Expert Advisory Panel on selective COX- 2 inhibitor NSAIDs

Terms of Reference

• 2005-05-24
  

Membership

• 2005-06-03
• Affiliation and Interest Summary for Panel members (PDF)
  

Meetings

• 2005-06-09/10
  • Agenda
  • Data and Evidence
  • Expert Advisory Panel Report
  • Health Canada Comments on the Report from Expert Advisory Panel on the Safety of COX-2 Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Report on the Cardiovascular Risks Associated with COX-2-Selective Non-Steroidal Anti-Inflammatory Drugs

Public Forum

• Main page
• Questions for the Expert Advisory Panel
• The Public Forum - What it is and how it works
• Health Canada's review of COX-2 safety data
• Public Input
• Participant Voluntary Information Summary (PDF)
  
  
• Health Canada Presentations at the forum
• Presentation of the Marketed Products Directorate, Health Canada - Overview of the issue and questions to the Panel - Dr. Maria Valois (PDF)
• Presentation of the Office of Consumer and Public Involvement - Summary of the public input - Ms. Sylvie Cantin (PDF)
• Presentation of the Marketed Health Products Directorate - Post-market information - Dr. Dominique Heon (PDF)
• Presentation of the Therapeutic Products Directorate - Pre-market information - Dr. Maurica Maher (PDF)
  
  
• Company Material
• Data and evidence on specific COX-2 products
• Novartis - Lumiracoxib (COX189) (PDF)
• Pfizer - Valdecoxib (Bextra) (PDF)
• Pfizer - Celecoxib (Celebrex) (PDF)
  
  
• Company Presentations at the forum
• Novartis (PDF)
• Pfizer
• Celecoxib (PDF)
• Valdecoxib (PDF)
• Merck (PDF)
  
  
• Evaluation Form
• If you have any comments, please complete the MSWord version of the evaluation form and return it to ocapi-bpcp@hc-sc.gc.ca.
• MSWord format The next link will open the Microsoft Word document in a new window. (To be completed and returned to: ocapi-bpcp@hc-sc.gc.ca)
• HTML format (for reference only)